Reconstituting the immune killing functions and improving the pharmacokinetics of nanobodies by rhamnolipid conjugation
Journal of Controlled Release · 2025
DOI: 10.1016/j.jconrel.2024.11.080 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2025. Verfasst von Yanchun Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi 214122, China. Hauptthemen laut MEDLINE: Glycolipids, Single-Domain Antibodies, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangsu Province, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
Nanobodies (Nbs) hold great promise as next-generation cancer immunotherapies, but their efficacy is hindered by their poor pharmacokinetics and the inability to trigger Fc-mediated immune killing functions. To address these limitations, we designed and synthesized rhamnolipid-modified Nbs as a type of antibody-recruiting molecule by site-specifically conjugating EGFR-targeting Nb 7D12 to a series of rhamnolipid derivatives, and their biological profiles were evaluated in vitro and in vivo. Investigation of the structure-activity relationship revealed that the number of rhamnose (Rha) units and the length of the PEG linker in the conjugates affected anti-tumor activities. Conjugate R5, which contained two Rha units and a PEG2 linker, exhibited the most potent antibody-dependent cell-mediated phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC) activities. In vivo, R5 had a significantly longer half-life because of its ability to bind to serum albumin and endogenous anti-Rha antibodies, and it demonstrated potent in vivo antitumor activity in a xenograft mouse model of A431 tumor. Our findings highlight the potential of rhamnolipidation as a strategy to enhance the efficacy of Nbs in cancer immunotherapy and provide a cost-effective platform for improving the therapeutic efficiency of Nbs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi 214122, China.
- Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi 214122, China. Electronic address: haofei@jiangnan.edu.cn.
- Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi 214122, China. Electronic address: zwu@jiangnan.edu.cn.
Förderung
- Natural Science Foundation of Jiangsu Province
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Li, Y., Li, D., Lin, H., Wang, D., Zhao, J., Wang, Z., Hong, H., & Wu, Z. (2025). Reconstituting the immune killing functions and improving the pharmacokinetics of nanobodies by rhamnolipid conjugation. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.11.080
Vancouver
Li Y, Li D, Lin H, Wang D, Zhao J, Wang Z, et al. Reconstituting the immune killing functions and improving the pharmacokinetics of nanobodies by rhamnolipid conjugation. Journal of Controlled Release. 2025. doi:10.1016/j.jconrel.2024.11.080
BibTeX
@article{Li2025,
author = {Li, Yanchun and Li, Dan and Lin, Han and Wang, Di and Zhao, Jie and Wang, Zheng and Hong, Haofei and Wu, Zhimeng},
title = {Reconstituting the immune killing functions and improving the pharmacokinetics of nanobodies by rhamnolipid conjugation},
journal = {Journal of Controlled Release},
year = {2025},
doi = {10.1016/j.jconrel.2024.11.080}
}
EUVIMED